Table 3.

Summary of primary and secondary outcomes (from baseline to 10 weeks).

Primary endpoint: visual acuity (logMAR)
	Mean change from baseline	95% CI	p1	Number of subjects with ≥0.2 logMAR improvement	Mean treatment group difference	95% CI	p2
Control	−0.194	−0.254 to −0.133	<0.001	8 (40.0%)	0.027	−0.057 to 0.110	0.524
Fluoxetine	−0.167	−0.226 to −0.108	<0.001	9 (42.8%)
Secondary endpoint: binocular vision (Bagolini striated glass test)
	Number of subjects with improved binocular vision			p 2
Control	4 (23.5%)			p = 0.478
Fluoxetine	2 (10.0%)
Secondary endpoint: contrast sensitivity (Pelli-Robson chart)
	Number of subjects with improved contrast sensitivity			p 3
Control	0 (0%)			N/A
Fluoxetine	2 (10.0%)
Secondary endpoint: crowded near visual acuity (Landolt C ring chart)
	Mean change from baseline		95% CI	p 1	p 2
Control	0.181		0.126 to 0.236	<0.001	p = 0.381
Fluoxetine	0.148		0.095 to 0.201	<0.001

¹Change from baseline to 10 weeks.

²Treatment group difference at 10 weeks.

³Contrast sensitivity was not analyzed statistically as there was practically no variation in the control group. Only two patients in the whole patient population had significant contrast sensitivity impairment at baseline. Both were in the fluoxetine group and both improved to almost normal contrast sensitivity from baseline to 10 weeks.